The field of drug discovery is challenging and time-consuming, but generative artificial intelligence (AI) has the potential to revolutionize this process. Generative AI, a subfield of AI, focuses on creating new data instances that resemble existing data. In the context of drug discovery, it involves generating molecular structures.
Generative AI in drug discovery has become a lucrative sector, with the market expected to be worth around USD 1,417.83 million by 2032. The role of generative AI is to expedite the process of identifying potential therapeutic molecules and optimize drug designs.
By leveraging machine learning algorithms like generative adversarial networks (GANs), recurrent neural networks (RNNs), and graph neural networks (GNNs), generative AI can generate novel molecular structures, optimize drug designs, and facilitate de novo drug design. This enables researchers to explore a vast chemical space and identify promising drug candidates.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.